Pacific Biosciences of California, Inc. (PACB) is a publicly traded Healthcare sector company. As of October 19, 2026, PACB trades at $1.80 with a market cap of $537.74M and a P/E ratio of -6.20. PACB moved +4.05% today. Year to date, PACB is -7.49%; over the trailing twelve months it is -1.70%. Its 52-week range spans $0.85 to $3.44. Analyst consensus is neutral with an average price target of $1.90. Rallies surfaces PACB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for PACB, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $1.80 |
| Market Cap | $537.74M |
| P/E Ratio | -6.20 |
| EPS | $-0.43 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.44 |
| 52-Week Low | $0.85 |
| Volume | 2.59M |
| Avg Volume | 0 |
| Revenue (TTM) | $159.27M |
| Net Income | $-131.39M |
| Gross Margin | 36.38% |
5 analysts cover PACB: 0 strong buy, 2 buy, 2 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $1.90.